CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 94 filers reported holding CONCERT PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $4,523 | -99.9% | 774,922 | +17.0% | 0.00% | -50.0% |
| Q3 2022 | $4,436,000 | +29.1% | 662,100 | -18.9% | 0.00% | +100.0% |
| Q2 2022 | $3,437,000 | +31.0% | 816,173 | +4.8% | 0.00% | 0.0% |
| Q1 2022 | $2,624,000 | +16.5% | 778,596 | +8.9% | 0.00% | 0.0% |
| Q4 2021 | $2,252,000 | -7.4% | 714,736 | -3.9% | 0.00% | 0.0% |
| Q3 2021 | $2,431,000 | -34.6% | 743,373 | -15.6% | 0.00% | 0.0% |
| Q2 2021 | $3,717,000 | -26.1% | 880,865 | -12.6% | 0.00% | -50.0% |
| Q1 2021 | $5,027,000 | -63.1% | 1,007,495 | -6.6% | 0.00% | -60.0% |
| Q4 2020 | $13,641,000 | +26.9% | 1,079,170 | -1.4% | 0.01% | 0.0% |
| Q3 2020 | $10,748,000 | -3.5% | 1,094,575 | -2.2% | 0.01% | 0.0% |
| Q2 2020 | $11,135,000 | +12.0% | 1,119,190 | -0.5% | 0.01% | 0.0% |
| Q1 2020 | $9,944,000 | -10.8% | 1,124,820 | -7.0% | 0.01% | +25.0% |
| Q4 2019 | $11,152,000 | +59.2% | 1,209,001 | +1.5% | 0.00% | +33.3% |
| Q3 2019 | $7,004,000 | -50.6% | 1,191,108 | +0.8% | 0.00% | -50.0% |
| Q2 2019 | $14,186,000 | +3.1% | 1,182,186 | +3.8% | 0.01% | +20.0% |
| Q1 2019 | $13,754,000 | -2.9% | 1,139,433 | +0.9% | 0.01% | -16.7% |
| Q4 2018 | $14,171,000 | -10.7% | 1,129,166 | +5.6% | 0.01% | 0.0% |
| Q3 2018 | $15,872,000 | -0.0% | 1,069,495 | +13.4% | 0.01% | 0.0% |
| Q2 2018 | $15,879,000 | -6.0% | 943,442 | +27.9% | 0.01% | -14.3% |
| Q1 2018 | $16,892,000 | +96.6% | 737,646 | +122.1% | 0.01% | +75.0% |
| Q4 2017 | $8,590,000 | +116.6% | 332,054 | +23.5% | 0.00% | +100.0% |
| Q3 2017 | $3,966,000 | -5.8% | 268,889 | -10.9% | 0.00% | 0.0% |
| Q2 2017 | $4,212,000 | -18.2% | 301,940 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $5,150,000 | +61.8% | 301,940 | -2.4% | 0.00% | 0.0% |
| Q4 2016 | $3,183,000 | -2.7% | 309,361 | -4.4% | 0.00% | 0.0% |
| Q3 2016 | $3,272,000 | -11.3% | 323,724 | -1.4% | 0.00% | 0.0% |
| Q2 2016 | $3,689,000 | -15.1% | 328,467 | +3.3% | 0.00% | -33.3% |
| Q1 2016 | $4,343,000 | +2.0% | 318,015 | +41.8% | 0.00% | 0.0% |
| Q4 2015 | $4,256,000 | +411.5% | 224,348 | +405.9% | 0.00% | +200.0% |
| Q3 2015 | $832,000 | – | 44,350 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 4,420,349 | $25,814,838 | 3.96% |
| Parkman Healthcare Partners LLC | 1,203,484 | $7,028,347 | 1.87% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,002,783 | $5,856,253 | 1.26% |
| TANG CAPITAL MANAGEMENT LLC | 1,150,000 | $6,716,000 | 0.98% |
| BVF INC/IL | 3,629,000 | $21,193,360 | 0.89% |
| Nantahala Capital Management | 1,732,388 | $10,117,146 | 0.66% |
| AWM Investment Company, Inc. | 666,661 | $3,893,300 | 0.56% |
| INGALLS & SNYDER LLC | 1,295,833 | $7,568 | 0.41% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 200,800 | $1,172,672 | 0.36% |
| Kensington Investment Counsel, LLC | 58,599 | $342,218 | 0.27% |